N/A N=141 Randomized Treatment

Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder

Bottom Line

View on ClinicalTrials.gov: NCT01259596 ↗

Enrolled (actual)

141

Serious AEs

0.0%

Results posted

Oct 2017

Primary outcome: Primary: Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13 — -9.44; -5.37 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: cognitive behavioral therapy (Behavioral); nondirective supportive therapy (Behavioral)
Age: Adult, Older Adult · 60+ yrs
Sex: All
Sponsor: Wake Forest University Health Sciences
Primary completion: Feb 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13	-9.44; -5.37	—
PRIMARY Changes From Baseline in Hamilton Anxiety Rating Scale (HAM-A) at Week 13	-7.04; -5.53	—
SECONDARY Changes From Baseline in Beck Depression Inventory (BDI) at 13 Weeks	-10.77; -7.54	—
SECONDARY Pepper Center Tool for Disability (PCT-D)	1.71; 1.86	—
SECONDARY Short Form (36) Health Survey (SF-36) to Week 13	60.5; 53.5	—
SECONDARY Insomnia Severity Index (ISI)	8.70; 11.9	—
SECONDARY Changes From Baseline in Generalized Anxiety Disorder-7 (GAD-7) to Week 13	-5.63; -3.27	—

Summary

The purpose of this study is to determine if cognitive-behavioral therapy (CBT)and supportive therapy delivered by telephone are effective for reducing worry and anxiety in rural older adults with Generalized Anxiety Disorder (GAD).

Eligibility Criteria

Inclusion Criteria

60 years GAD Reside in rural county Proficient in English

Exclusion Criteria

Current psychotherapy Active alcohol or substance abuse with use within last month Dementia or global cognitive impairment Psychotic symptoms Active suicidal ideation with plan and intent Change in psychotropic medications within last 1 month Significant hearing loss

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01259596). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.